310 related articles for article (PubMed ID: 9820883)
1. Bisphosphonates in bone diseases.
Sparidans RW; Twiss IM; Talbot S
Pharm World Sci; 1998 Oct; 20(5):206-13. PubMed ID: 9820883
[TBL] [Abstract][Full Text] [Related]
2. Rationale for the use of alendronate in osteoporosis.
Kanis JA; Gertz BJ; Singer F; Ortolani S
Osteoporos Int; 1995 Jan; 5(1):1-13. PubMed ID: 7703618
[TBL] [Abstract][Full Text] [Related]
3. New bisphosphonates in the treatment of bone diseases.
Gatti D; Adami S
Drugs Aging; 1999 Oct; 15(4):285-96. PubMed ID: 10582775
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates: preclinical aspects and use in osteoporosis.
Fleisch HA
Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
[TBL] [Abstract][Full Text] [Related]
5. The pharmacology and therapeutic utility of bisphosphonates.
Lourwood DL
Pharmacotherapy; 1998; 18(4):779-89. PubMed ID: 9692651
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.
Fleisch H
Drugs; 1991 Dec; 42(6):919-44. PubMed ID: 1724640
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates: from the laboratory to the clinic and back again.
Russell RG; Rogers MJ
Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates and the treatment of bone disease in the elderly.
Johansen A; Stone M; Rawlinson F
Drugs Aging; 1996 Feb; 8(2):113-26. PubMed ID: 8845585
[TBL] [Abstract][Full Text] [Related]
9. Risedronate: a new oral bisphosphonate.
Umland EM; Boyce EG
Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates for prevention of postmenopausal osteoporosis.
Ravn P
Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
[TBL] [Abstract][Full Text] [Related]
11. Clinical trials with bisphosphonates.
Lombardi A; Santora AC
Ann Ital Med Int; 1992; 7(3 Suppl):158S-165S. PubMed ID: 1297394
[TBL] [Abstract][Full Text] [Related]
12. New bisphosphonates in osteoporosis.
Fleisch H
Osteoporos Int; 1993; 3 Suppl 2():S15-22. PubMed ID: 8481594
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
Miller PD
Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates in the treatment of osteoporosis.
Bell NH; Johnson RH
Endocrine; 1997 Apr; 6(2):203-6. PubMed ID: 9225137
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
16. Discovery, clinical development, and therapeutic uses of bisphosphonates.
Licata AA
Ann Pharmacother; 2005 Apr; 39(4):668-77. PubMed ID: 15755793
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates in prostate carcinoma.
Adami S
Cancer; 1997 Oct; 80(8 Suppl):1674-9. PubMed ID: 9362435
[TBL] [Abstract][Full Text] [Related]
18. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
Chapurlat RD; Delmas PD
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates in the treatment of disorders of mineral metabolism.
Singer FR; Minoofar PN
Adv Endocrinol Metab; 1995; 6():259-88. PubMed ID: 7671099
[TBL] [Abstract][Full Text] [Related]
20. Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis.
McClung MR
Bone; 1996 Nov; 19(5 Suppl):195S-198S. PubMed ID: 8922662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
